Abbott Laboratories (ABT)
About Abbott Laboratories
What is Abbott Laboratories?
Abbott Laboratories is one of the world’s largest healthcare companies. Founded in 1888 and headquartered in Illinois, the company sells medical devices, diagnostics, generic medicines, and nutritional products. Through mergers and acquisitions, Abbot’s is now a multinational operating in 160 countries with more than 100,000 employees, 31 manufacturing sites, and 12 development centres globally. Some of its best-known products include baby formula Similac and nutritional supplement company, Ensure.
How does Abbott Laboratories make money?
It makes money from selling medical devices, pharmaceuticals, and nutritional products. Abbotts has four operational segments: Medical devices, Nutritionals, diagnostics, and pharmaceutical products. It conducts research and development before selling its products to hospitals, government agencies, pharmacies, and retail consumers worldwide.
What is Abbott Laboratories’ best selling product?
Medical devices are Abbott Laboratories’ best selling products. Its cardiovascular and neuromodulation products generate the most revenue for the business. In 2021, medical devices accounted for $13.9 billion of its $36.6 billion revenue. Its second biggest driver in revenue is its nutritional products which made $8.2 in 2021.
Who are the key executives at Abbott Laboratories?
Robert Ford has been at the company since 1996 and became its CEO in 2020. Here are a few other key executives at Abbott Laboratories.
- Robert Ford. Chief Executive Officer and President
- Robert E. Funck Jr. Executive Vice President
- Hubert L. Allen. Executive Vice President
- Daniel Gesua Sive Salvadori. Executive Vice President of Established Pharmaceuticals & Nutritional Products
- Andrea F. Wainer. Executive Vice President of Rapid & Molecular Diagnostics
- Scott Michael Leinenweber. Vice President of Investor Relations
- James E. Young. Chief Compliance Officer
- Melissa Brotz. Vice President of Marketing
- Elaine R. Leavenworth. Chief Marketing & External Affairs Officer
- Mary K. Moreland. Vice President of Human Resources
Where can I buy shares in Abbott Laboratories?
You can buy Abbott Laboratories stock on a stock trading platform. These platforms are extremely simple to use but there are different options to suit your specific needs. If you are a first-time investor you might want to use a trading platform for beginners, while if you plan on doing a lot of trading from your phone, a stock trading app might be best.
Are there any other ways to invest in Abbott Laboratories ?
The simplest way to invest in Abbott Laboratories is to buy shares through a stock broker. However, you can also invest through an ETF or a fund. The best ETFs allow you to invest in the stock market more generally rather than focus on one company.
Abbott Laboratories is part of the NYSE index, so you can invest in an ETF that tracks that index, or choose a healthcare ETF that lets you own a basket of related stocks from the same industry.
More about the ABT price
What is the Abbott Laboratories stock price today?
The ABT stock price today is currently $98.29, as of October 2022. The price of Abbott Laboratories is down 30% in 2022. You can use the live Abbott Laboratories stock chart to track the NYSE:ABT price in real time above or compare the Abbott Laboratories value today to its past performance using the Abbott Laboratories financials tab at the top of this page.
What is the 52-week low for Abbott Laboratories stock?
The 52-week low for Abbott Laboratories stock is $93.25. ABT stock is currently 5% above the 52-week low.
What is the 52-week high for Abbott Laboratories stock?
The 52-week high for Abbott Laboratories stock was $142.60. ABT stock is currently 30% below the 52-week high.
What is the stock forecast for Abbott Laboratories?
The average Abbott Laboratories stock forecast has a price target of $117.90 by the end of 2022. Abbott Laboratories’ latest financial results, the broader economic outlook, and the amount of competition in the industry all influence these forecasts.
It’s best to take analyst forecasts with a grain of salt, but you can use their estimates to help you understand the weight of opinion about a stock.
More stock guides
Abbott Laboratories’ market capitalisation is $166.47 billion. This is calculated by multiplying the number of shares that have been issued by the current ABT share price. Another way of measuring this is enterprise value, which includes Abbott Laboratories’ debt obligations. Abbott Laboratories’ enterprise value is $173.94 billion.
Abbott Laboratories went public in 1929 with a listing on the Chicago Stock Exchange. That was the same year as the stock market crash that began the Great Depression.
The biggest shareholder of Abbott Laboratories is The Vanguard Group which owns over 8% of the company. Many other institutions and funds own chunks of ABT stock, including Black Rock with 5% and Morgan Stanley with 1%.
Abbott operates in the healthcare industry, so it has competition from many companies. Here are some of its biggest competitors.
- Johnson & Johnson. Johnson & Johnson is one of the best known healthcare companies worldwide.
- GlaxoSmithKline. GSK is a British pharmaceutical company and one of the best dividend-paying stocks.
- Pfizer. Pfizer is a major player in the pharmaceutical industry and one of the few companies to develop a coronavirus vaccine.
Abbott Laboratories has had seven stock splits in its history. Its first was in 1975 and its most recent in 1998. Every split has been a 2-for-1, which means for every 1 share an investor holds, they receive 2. Businesses use stock splits to lower their share price and attract new investors.
Abbotts reports earnings four times a year at quarterly intervals. It reports in March, June, September, and December.
Yes, it’s known as a ‘dividend king’ and has declared one for the past 394 quarters. It has also increased its dividend payment for 50 consecutive years, making it part of the dividend aristocrat index.
Recent Abbott Laboratories news
Latest Abbott Laboratories price analysis
Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >